Exicure to sell GPC-100 (burixafor) assets to Korea's GPCRT for KRW 6.5B (~US$4.8M)

EXICURE, INC.

Aggregate cash price KRW 6.5B (~US$4.8M): KRW 500M deposit already paid and credited, KRW 2.0B due by November 16, 2026, KRW 4.0B at closing.
Assets: rights under the January 19, 2025 License and Collaboration Agreement with GPCR Therapeutics, plus IP, clinical/regulatory data, materials and equipment.
GPCRT assumes post-closing obligations including future milestone and royalty payments to GPCR, and bears GPC-100 program costs incurred on or after September 1, 2026.
GPC-100 was evaluated with propranolol for stem cell mobilization in multiple myeloma; GPCR USA completed its Phase 2 trial in January 2026.
Closing needs board approvals, regulatory and third-party consents, a GPCR waiver/release, and any required Exicure stockholder approval; timing not assured.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.